Skip to main content

Advertisement

SpringerLink
Log in

Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

The optimal treatment for hilar or mediastinal lymph node (LN) recurrence developing after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer remains unclear. This study evaluated 5-year results of radiotherapy in such patients in comparison with those for postoperative LN metastases.

Materials and methods

Between 2004 and 2013, 27 patients with hilar and/or mediastinal LN metastases without local recurrence and distant metastasis after SBRT (n = 14) or surgery (n = 13) were treated with definitive conventional radiotherapy. The median total dose for treating metastatic LN was 60 Gy for the post-SBRT group and 66 Gy for the post-surgery group.

Results

The median follow-up for the 5 surviving patients was 62 months. The overall survival, cause-specific survival, progression-free survival, and local control rates at 5 years after mediastinal irradiation were 14%, 45%, 21%, and 58%, respectively, for the 14 patients in the post-SBRT group. These rates were 36%, 45%, 39%, and 92%, respectively for the post-surgery group (p = 0.066, 0.64, 0.38, and 0.41, respectively). Four patients in the post-SBRT group survived 3 or more years (range 36–92 months) after mediastinal irradiation.

Conclusions

A proportion of patients in both groups achieved long-term survival by conventional radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.

    Article  Google Scholar 

  2. Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a–T2bN0M0) non-small-cell lung cancer. J Thorac Oncol. 2013;8:726–35.

    Article  CAS  Google Scholar 

  3. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989–96.

    Article  Google Scholar 

  4. Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10:960–4.

    Article  CAS  Google Scholar 

  5. Wink KCJ, van Baardwijk A, Troost EGC, De Ruysscher D.  Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: incidence and proposed risk factors. Cancer Treat Rev. 2017;56:8–15.

    Article  Google Scholar 

  6. Manabe Y, Shibamoto Y, Baba F, Murata R, Yanagi T, Hashizume C, et al. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer. Pract Radiat Oncol. 2012;2:e137–43.

    Article  Google Scholar 

  7. Hayashi K, Yamamoto N, Karube M, Nakajima M, Tsuji H, Ogawa K, et al. Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors. Cancer Sci. 2018;109:1562–9.

    Article  CAS  Google Scholar 

  8. McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109:38–44.

    Article  Google Scholar 

  9. Ward MC, Oh SC, Pham YD, Woody NM, Marwaha G, Videtic GM, et al. Isolated nodal failure after stereotactic body radiotherapy for lung cancer: the role for Salvage mediastinal radiotherapy. J Thorac Oncol. 2016;11:1558–64.

    Article  Google Scholar 

  10. Baba F, Shibamoto Y, Tomita N, Ikeya-Hashizume C, Oda K, Ayakawa S, et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol. 2009;4:15.

    Article  Google Scholar 

  11. Rulach R, Hanna GG, Franks K, McAleese J, Harrow S. Re-irradiation for locally recurrent lung cancer: evidence, risks and benefits. Clin Oncol (R Coll Radiol). 2018;30:101–09.

    Article  CAS  Google Scholar 

  12. Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367–72.

    Article  Google Scholar 

  13. Ono T, Nakamura T, Yamaguchi H, Azami Y, Takayama K, Suzuki M, et al. Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer. Radiat Oncol. 2018;13:19.

    Article  Google Scholar 

  14. Okami J, Nishiyama K, Fujiwara A, Konishi K, Kanou T, Tokunaga T, et al. Radiotherapy for postoperative thoracic lymph node recurrence of non-small-cell lung cancer provides better outcomes if the disease is asymptomatic and a single-station involvement. J Thorac Oncol. 2013;8:1417–24.

    Article  Google Scholar 

  15. Kim E, Song C, Kim MY, Kim JS. Long-term outcomes after salvage radiotherapy for postoperative locoregionally recurrent non-small-cell lung cancer. Radiat Oncol J. 2017;35:55–64.

    Article  Google Scholar 

  16. Seol KH, Lee JE, Cho JY, Lee DH, Seok Y, Kang MK. Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer. Thorac Cancer. 2017;8:620–29.

    Article  Google Scholar 

  17. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

    Article  CAS  Google Scholar 

  18. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

    Article  Google Scholar 

  19. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

    Article  CAS  Google Scholar 

  20. Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, et al. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci. 2016;107:1837–42.

    Article  CAS  Google Scholar 

  21. Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, et al. Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:568–76.

    Article  Google Scholar 

Download references

Acknowledgements

A part of this work was presented at the ASTRO’s 59th Annual Meeting, San Diego, September 24–27, 2017. We thank all staffs of the radiation oncology section.

Author information

Authors and Affiliations

  1. Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

    Yoshihiko Manabe, Yuta Shibamoto, Takeshi Yanagi, Hiromitsu Iwata, Akifumi Miyakawa & Taro Murai

  2. Department of Radiotherapy, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya, 462-8508, Japan

    Fumiya Baba

  3. Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya, 462-8508, Japan

    Hiromitsu Iwata

  4. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

    Katsuhiro Okuda

Authors
  1. Yoshihiko Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuta Shibamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumiya Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromitsu Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akifumi Miyakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taro Murai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuhiro Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiko Manabe.

Ethics declarations

Conflicts of interest

None declared.

Ethical standards

All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manabe, Y., Shibamoto, Y., Baba, F. et al. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results. Jpn J Radiol 36, 719–725 (2018). https://doi.org/10.1007/s11604-018-0776-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-018-0776-6

Keywords

Search

Navigation